Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.

We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.

Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.

Please see our Terms of Service and Privacy Policy.

Emerging Therapy

DBV Submits VIASKIN Peanut Patch for FDA Approval Following Phase 3 Success

Aquestive Resubmits Needle-Free Sublingual Epinephrine to FDA for Approval

Potential Breakthrough for Celiac Disease: Teva Antibody Significantly Reduces Gluten-Induced Gut Damage

Rare Antibodies Could Lead to First Targeted Treatment for Alpha-Gal Syndrome

Another Potential Food Allergy Treatment is Snapped Up by Big Pharma

FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment...

Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development...

End Allergies Together Announces Winners of $1 Million Grand Challenge to...

FDA Opens Door for Clinical Development of Aquestive Therapeutics Anaphylaxis Treatment

Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development...

What You Need to Know About the First Peanut Allergy Treatment...

FDA Approves Aimmune’s PALFORZIA as First Treatment for Peanut Allergy

Allergy Therapeutics Publishes Encouraging New Data for Peanut Allergy Vaccine Candidate

Intrommune’s Food Allergy Toothpaste Therapy to Advance to Clinical Trials

DBV Technologies Reports Positive Three-Year, Long Term Data from Phase III...

Follow Us

Your School On Our Map

Put Your School on the Map